Clonazolam Powder, also known as clonitrazolam, is a synthetic benzodiazepine derivative belonging to the triazolobenzodiazepine family. The compound was synthesized during the 1970s but was never developed as an approved pharmaceutical medicine. It later appeared as a novel psychoactive substance.
Product In-Stock: InStock
Advanced Clonazolam Powder | Potent Benzodiazepine Profile & Properties
Clonazolam Powder, also known as clonitrazolam, is a synthetic benzodiazepine derivative belonging to the triazolobenzodiazepine family. The compound was synthesized during the 1970s but was never developed as an approved pharmaceutical medicine. It later appeared as a novel psychoactive substance.
Clonazolam has a molecular formula of C17H12ClN5O2 and a reported molecular weight of approximately 353.77 g/mol. Its IUPAC designation is 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.
The pharmacological characteristics of Clonazolam Powder are associated with the benzodiazepine class, which acts primarily through the GABAergic system in the central nervous system. Benzodiazepine-type activity can produce sedation, anxiolytic effects, muscle relaxation, impaired coordination, and changes in memory and consciousness.
Clonazolam is notable for its high potency relative to many established benzodiazepines. Reported effects have included pronounced sedation and amnesia, with the potential for significant central nervous system depression. These characteristics make the compound particularly important in toxicological and forensic analysis.
The available clinical information concerning clonazolam is limited. Its pharmacokinetics, long-term effects, therapeutic potential, toxicity, and interactions have not been characterized to the same extent as approved benzodiazepine medicines.
As with other potent benzodiazepine-type substances, combining clonazolam with alcohol, opioids, or other central nervous system depressants can increase the risk of severe sedation and potentially life-threatening respiratory depression. Dependence and withdrawal are also important considerations associated with benzodiazepine-class compounds.
Clonazolam Powder should therefore be regarded as a novel psychoactive benzodiazepine rather than an established therapeutic medication. Its properties and risks should be evaluated within an appropriate scientific, toxicological, and regulatory framework.
